Q-omics provides the consensus-scored CELA2B profile across patient tissues and cancer cell-line models. CELA2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CELA2B is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, CELA2B RNA expression shows 18,346 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LUAD, and UVM as cancer lineages where CELA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CELA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CELA2B survival associations across molecular data types. CELA2B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CELA2B RNA expression–survival associations across cancer types. High CELA2B expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, BRCA, UCS and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CELA2B RNA expression.
This table summarizes CELA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CELA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CELA2B shows lower tumor expression in LUAD, KICH, LUSC, BLCA, THCA and UCEC. The LUAD box plot shows higher CELA2B RNA expression in normal versus tumor tissue (log2 FC = −1.015, t-test p < 0.001).
This table shows molecular features associated with CELA2B in patient tissues and cancer cell lines. In patient samples, CELA2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CELA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
